Peptide Cycling for Powerlifters: User Practice and Evidence

Why Peptides Seem to Stop Working

A common story on lifting forums: a few months into a protocol, the results slow down. The scale stops moving and the recovery isn't as rapid. Users start wondering if their source went bad, which can't be ruled out, but community guides usually blame adaptation.

The main reason lifters give for cycling peptides, especially growth hormone secretagogues like ipamorelin, is receptor desensitization. Ipamorelin and other GHRPs dock with the Growth Hormone Secretagogue Receptor (GHSR) on the pituitary, which signals the cell to release growth hormone. (CJC-1295 is a GHRH analog and uses a different receptor.) In cell studies, the GHSR desensitizes within minutes of stimulation and is pulled inside the cell, and surface binding takes about 6 hours to recover. The forum reasoning is that weeks of constant signaling leave fewer receptors, so the same dose of peptide produces a weaker signal.

The human data are less clear-cut. In a 16-week study of 12 healthy older adults given hexarelin injections twice daily, the GH response fell by about a third in the first month and by about 45% at week 16, but it didn't disappear. Four weeks after stopping, it was back to baseline. GH and IGF-1 stayed at young-adult levels throughout a 2-year trial of daily oral MK-677 (25 mg) in 65 adults aged 60-81. Partial tolerance looks real, but no human study has compared cycling schedules.

Users also point to negative feedback loops. When GH rises, your liver produces more IGF-1, and high IGF-1 feeds back on the hypothalamus and pituitary, partly through somatostatin, which is a 'stop' signal for GH release. The community argument is that cycling gives these feedback loops time to reset to their natural baseline. That's plausible, but in the MK-677 trial feedback didn't cancel out daily dosing over 2 years.

The Difference Between 'Cycling' and Just 'Stopping'

The word gets thrown around, but users describe three different strategies for different goals.

1. The Classic Cycle (On and Off): Users run a peptide stack for a defined period, typically 8-16 weeks, to match a goal like a massing phase or a fat-loss cut, then take a clean break of at least 4 weeks. Community guides say this is long enough to resensitize receptors and let the GH axis (the hypothalamic-pituitary-somatotropic axis) normalize. The hexarelin data fit a 4-week break, but no one has tested shorter or longer ones.

2. The Intra-Week Pulse (5-On, 2-Off): This is a popular one you'll see on forums. Users run their protocol from Monday to Friday and take the weekend off, to give the receptors a short break every week. The evidence for this being better than a classic cycle is thin; nobody has tested it. Some users treat it as a compromise, and many still take a full break eventually.

3. Injury-Driven Use (As Needed): This isn't really a 'cycle' in the hormonal sense. This applies to healing peptides like BPC-157 and TB-500, where users describe the goal as supporting a finite repair process. Most report running the peptide until the injury is resolved or significantly improved, then stopping. Users see no need for a 12-week run if a tendon feels better in four.

Practical Cycling Protocols for Secretagogues

The most commonly cycled category is GHRH analogs like CJC-1295 and GHRPs like ipamorelin and GHRP-2. (Tesamorelin, also a GHRH analog, is a prescription medicine for abdominal fat in HIV-associated lipodystrophy.) In a 1990 study of 18 healthy men, a GHRP given by IV with GHRH released more GH than either alone, which is why users pair them. No trial has tested the popular CJC-1295 (no DAC) plus ipamorelin stack, or whether stacking speeds up desensitization. Our guide to how users combine peptides covers stacking.

Here's how the schedules users describe compare for CJC-1295 (no DAC, also called Mod GRF 1-29) + ipamorelin, which users commonly report at 100-300 mcg of each by subcutaneous injection, often at bedtime. None has been tested in a trial.

During the 'on' period, users typically describe injecting 1-3 times per day; the 'off' period means zero injections. Community guides say there's no need to taper secretagogues because there's no known withdrawal or hormonal crash to manage. No study has compared tapering with stopping outright.

For tested powerlifters, the schedule doesn't matter: WADA's 2026 Prohibited List bans GHRH analogs such as CJC-1295 at all times under S2.2.4, and the same section names ipamorelin and MK-677 as GH secretagogues. More on what the WADA lists mean for tested athletes.

And What About BPC-157 and TB-500?

These peptides don't operate on the same clear-cut hormonal feedback loops as secretagogues. In animal and cell studies, BPC-157 has been linked to higher growth hormone receptor expression and Angiogenesis (blood vessel formation) via the VEGF pathway; a 2025 systematic review found 35 of 36 studies were preclinical and found no clinical safety data. TB-500 is a fragment of thymosin beta-4, an actin-binding protein studied for cell migration. As of October 2026, WADA bans both at all times (BPC-157 under S0, TB-500 under S2.3).

Whether their targets desensitize hasn't been studied, and users rarely worry about it because the use case is entirely different.

• For an acute injury (e.g., a hamstring pull): Users commonly report running BPC-157 (often with TB-500) for a short, targeted duration: 250-500 mcg per day by subcutaneous injection, sometimes split into two doses, for 2-6 weeks, stopping when the pain and dysfunction are gone. The cycle length is dictated by the injury, not a calendar. No human dose-finding study exists; the only IV safety pilot gave 2 adults 10 mg and then 20 mg, with no reported side effects.
• For chronic issues or general recovery (e.g., lifter's elbow): Some users describe a longer, lower-dose run, such as 250 mcg daily for 8-12 weeks, then a month or two off to see whether the benefits have stuck. If the pain returns, many take that as a sign the peptide was managing symptoms, not fixing the root cause. Animal safety studies ran only up to 6 weeks.

In community practice, the 'off-cycle' for BPC-157 is simply the period after the injury has healed, and users still making progress at week 4 often continue. Our BPC-157 profile covers the evidence.

What We Still Don't Know

These schedules are community templates, not tested protocols. As of October 2026:

• Whether ipamorelin or GHRP-2 behave like hexarelin. The closest human data come from 12 older adults, not young lifters.
• Whether breaks change outcomes lifters care about. MK-677 raised fat-free mass over 2 years in older adults without improving strength or function, and no trial has measured strength with cycled secretagogues.
• How long BPC-157 use is safe. The safety data are animal studies of up to 6 weeks.

Many users treat the off period as a check: they keep training hard and watch whether recovery changes after they stop. That self-tracking is hard to read, because expectation effects and inconsistent product quality both blur the signal.